Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban

Takla R Anis, Whitney Jandreau Pharmacy Department, Northern Light Eastern Maine Medical Center, Bangor, ME, USACorrespondence: Takla R AnisPharmacy Department, Northern Light Eastern Maine Medical Center, 489 State Street, Bangor, ME, 04401, USAEmail takla.anis@gmail.comAbstract: Direct oral antico...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anis TR, Jandreau W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	apixaban rivaroxaban rash hypersensitivity Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/c06e393369324cfda8d742ffaee710fa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c06e393369324cfda8d742ffaee710fa
record_format	dspace
spelling	oai:doaj.org-article:c06e393369324cfda8d742ffaee710fa2021-12-02T15:17:58ZAnti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban1179-1438https://doaj.org/article/c06e393369324cfda8d742ffaee710fa2021-09-01T00:00:00Zhttps://www.dovepress.com/anti-xa-inhibitor-induced-hemorrhagic-pruritic-rash-a-case-report-on-p-peer-reviewed-fulltext-article-CPAAhttps://doaj.org/toc/1179-1438Takla R Anis, Whitney Jandreau Pharmacy Department, Northern Light Eastern Maine Medical Center, Bangor, ME, USACorrespondence: Takla R AnisPharmacy Department, Northern Light Eastern Maine Medical Center, 489 State Street, Bangor, ME, 04401, USAEmail takla.anis@gmail.comAbstract: Direct oral anticoagulants (DOACs) have gained increasing popularity in clinical practice in the past decade. While DOACs have fewer associated adverse events as compared to warfarin, DOAC-induced hypersensitivity is a rare adverse event that has been reported in the literature. We describe a case of apixaban-induced hemorrhagic pruritic rash in a 62-year-old man with protein C deficiency for which he was receiving warfarin. During hospitalization for another issue, his anticoagulant was converted to apixaban. Within 6 hours of receiving the first dose of apixaban, he developed a hemorrhagic pruritic rash around his buttocks area and extending into his groin. The following day, apixaban was replaced with rivaroxaban, while the rash continued to worsen and spread further around his back. After 3 days of DOAC therapy, the patient was reverted back to warfarin and within 24 hours the rash subsided. This case report indicates a potential rare adverse drug reaction that may become more prominent given the increasing utilization of DOACs in clinical practice. Future research is needed to further investigate this adverse event and ensure that providers and patients are aware of it. Additionally, this report documents to our knowledge, the first report of an immediate hypersensitivity reaction to DOACs.Keywords: apixaban, rivaroxaban, rash, hypersensitivityAnis TRJandreau WDove Medical PressarticleapixabanrivaroxabanrashhypersensitivityTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 13, Pp 181-184 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	apixaban rivaroxaban rash hypersensitivity Therapeutics. Pharmacology RM1-950
spellingShingle	apixaban rivaroxaban rash hypersensitivity Therapeutics. Pharmacology RM1-950 Anis TR Jandreau W Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
description	Takla R Anis, Whitney Jandreau Pharmacy Department, Northern Light Eastern Maine Medical Center, Bangor, ME, USACorrespondence: Takla R AnisPharmacy Department, Northern Light Eastern Maine Medical Center, 489 State Street, Bangor, ME, 04401, USAEmail takla.anis@gmail.comAbstract: Direct oral anticoagulants (DOACs) have gained increasing popularity in clinical practice in the past decade. While DOACs have fewer associated adverse events as compared to warfarin, DOAC-induced hypersensitivity is a rare adverse event that has been reported in the literature. We describe a case of apixaban-induced hemorrhagic pruritic rash in a 62-year-old man with protein C deficiency for which he was receiving warfarin. During hospitalization for another issue, his anticoagulant was converted to apixaban. Within 6 hours of receiving the first dose of apixaban, he developed a hemorrhagic pruritic rash around his buttocks area and extending into his groin. The following day, apixaban was replaced with rivaroxaban, while the rash continued to worsen and spread further around his back. After 3 days of DOAC therapy, the patient was reverted back to warfarin and within 24 hours the rash subsided. This case report indicates a potential rare adverse drug reaction that may become more prominent given the increasing utilization of DOACs in clinical practice. Future research is needed to further investigate this adverse event and ensure that providers and patients are aware of it. Additionally, this report documents to our knowledge, the first report of an immediate hypersensitivity reaction to DOACs.Keywords: apixaban, rivaroxaban, rash, hypersensitivity
format	article
author	Anis TR Jandreau W
author_facet	Anis TR Jandreau W
author_sort	Anis TR
title	Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
title_short	Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
title_full	Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
title_fullStr	Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
title_full_unstemmed	Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban
title_sort	anti-xa inhibitor-induced hemorrhagic pruritic rash: a case report on possible cross-reactivity between apixaban and rivaroxaban
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/c06e393369324cfda8d742ffaee710fa
work_keys_str_mv	AT anistr antixainhibitorinducedhemorrhagicpruriticrashacasereportonpossiblecrossreactivitybetweenapixabanandrivaroxaban AT jandreauw antixainhibitorinducedhemorrhagicpruriticrashacasereportonpossiblecrossreactivitybetweenapixabanandrivaroxaban
_version_	1718387472320167936

Anti-Xa Inhibitor-Induced Hemorrhagic Pruritic Rash: A Case Report on Possible Cross-Reactivity Between Apixaban and Rivaroxaban

Ejemplares similares